---
title: "INNOVENT BIO's match-patent for Bruton’s tyrosine kinase inhibitor has received official approval for new indications"
description: "INNOVENT BIO announced that the non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor Jepalitumab (Pirtobrutinib) has officially been approved by the National Medical Products Administratio"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277349493.md"
published_at: "2026-03-01T10:15:25.000Z"
---

# INNOVENT BIO's match-patent for Bruton’s tyrosine kinase inhibitor has received official approval for new indications

> INNOVENT BIO announced that the non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor Jepalitumab (Pirtobrutinib) has officially been approved by the National Medical Products Administration of China for a new indication, to be used in the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously received at least one systemic therapy including a BTK inhibitor

INNOVENT BIO (01801.HK) announced that the non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, Jebatilib (Pirtobrutinib), has officially received approval from the National Medical Products Administration of China for a new indication, to be used in the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously undergone at least one systemic therapy that included a BTK inhibitor

### Related Stocks

- [01801.HK - INNOVENT BIO](https://longbridge.com/en/quote/01801.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 在香港上市的中国制药公司有望通过销售增长和交易来实现转机 | 在香港上市的中国制药公司由于药品销售增长和丰厚的许可交易，正准备实现盈利。信达生物预计在 2025 年将首次实现全年的利润，达到 9.84 亿元人民币，主要得益于 45% 的收入增长。百济神州报告净利润为 2.8693 亿美元，得益于其成功 | [Link](https://longbridge.com/en/news/277340041.md) |
| 3.5 亿首付款、总额达 85 亿美元！信达生物与礼来合作布局肿瘤免疫新药研发 | 信达生物与礼来达成突破性合作，将联合开发肿瘤及免疫新药。此次交易预付款 3.5 亿美元，总额最高达 85 亿美元。双方摒弃传统授权，采用从零开始的共同研发模式，标志着中国药企创新力获全球顶尖药企深度认可，开启全球战略协作新篇章。 | [Link](https://longbridge.com/en/news/275269682.md) |
| 随着 Soficitinib 皮肤病试验的推进，审视诺诚健华（SEHK:9969）的估值 | 诺诚健华（SEHK:9969）在启动其 TYK2 抑制剂 soficitinib 的二期/三期临床试验后，吸引了投资者的关注。尽管股价表现不一，该股票被认为被低估，目前交易价格为 12.72 港元，而公允价值为 20.04 港元。公司拥有强 | [Link](https://longbridge.com/en/news/276680348.md) |
| 信达生物的第四季度收入增长了 60% | 信达生物第四季度收入激增 60% | [Link](https://longbridge.com/en/news/274820825.md) |
| Erasca 会议：ERAS 为 Pan-RAS ERAS-0015 和 Pan-KRAS ERAS-4001 项目预告 2026 年的催化剂 | Erasca（纳斯达克代码：ERAS）高管在一次炉边谈话中讨论了他们针对 RAS 驱动癌症的战略，并概述了即将到来的临床里程碑。他们强调了两个主要项目：ERAS-0015，一种全 RAS 抑制剂，以及 ERAS-4001，一种全 KRAS  | [Link](https://longbridge.com/en/news/277264882.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.